Centre National De La Recherche Scientifique

Université Paris—sud

Alaya.bio Inc.

Université Paris-saclay

Anna Miodek

Cécile Bauche

Renaud Vaillant

Frédéric Mourlane

Hafsa Korri-Youssoufi

Nawel Mejri

Philippe Bishop

An aptamer-based switch technology is provided that enhances control of the use of chimeric antigen receptor (CAR)-related immunotherapies. The aptamer-based switch utilizes a synthetic bridge molecule containing a target-binding aptamer bound through a linker to a CAR-binding aptamer. A system containing a CAR and a corresponding aptameric bridge provides an immunotherapy platform that: (i) can be targeted to any desired antigen by choosing the target-binding aptamer of the bridge. (ii) can be redirected from one target to another by changing the target-binding aptamer: (iii) can be dosed according to the changing needs of an individual patient overtime by altering the administration protocol for the bridge: (iv) can be switched on or off quickly or gradually: (v) can be used as a companion diagnostic for a specific CAR therapy: (vi) can be integrated with either in vivo or ex vivo CAR expression: (vii) is non-immunogenic; and (viii) has low production costs.

Aptamer-based CAR T-cell switch

A system for 'signal-on' electrochemical detection of molecules of interest and to a method implementing said system.

System for electrochemical detection of molecules of interest

Growing community of inventors

Orsay, France

Anna Miodek